Unum Therapeutics Inc(UMRX)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company’s product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company’s product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

Finance:
Market Cap:28.6M; Shares Outstanding:30.7M; Short Interest: 2.45%; Q3 2019(9/30/19): Cash 45.88M. Loss 11.92M

EPS and Sales:
https://finance.yahoo.com/quote/UMRX/financials?p=UMRX

Date EPS % last year % last quarter
2018.12.31 -1.39 44.62% -24.11%
2019.3.31 -0.39 40.91% 71.94%
2019.6.30 -0.73 8.75% -87.18%
2019.9.30 -1.12 0.00% -53.42%

 

Date Sales % last year % last quarter
2018.12.31 9.73M 16.44% 64.08%
2019.3.31 3.05M 37.52% -68.65%
2019.6.30 6.19M 59.32% 102.95%
2019.9.30 7.21M 21.62% 16.48%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=UMRX&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/UMRX/institutional-ownership/

2020.01.10:
Total institutions: 48,no change
Shares hold: 13243.2k shares. no change
shares% hold: 43.19%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/UMRX/price-targe

Leave a Reply